TRAF2 and acute myeloid leukemia: Further compelling evidence published by the same group demonstrated that LILRB3 expressed on AML cells recruits TRAF2 and cFLIP to stimulate NF-κB signaling, which enhances AML cell survival and impedes antitumor T cell activity (83).